Short Interest in Aptorum Group Limited (NASDAQ:APM) Drops By 75.1%

Aptorum Group Limited (NASDAQ:APM) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totaling 2,681 shares, a decline of 75.1% from the December 15th total of 10,748 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 61,744 shares, the short-interest ratio is currently 0.0 days. Based on an average daily trading volume, of 61,744 shares, the short-interest ratio is currently 0.0 days. Currently, 0.1% of the company’s stock are short sold.

Aptorum Group Stock Up 2.9%

Shares of Aptorum Group stock opened at $1.07 on Wednesday. The firm’s fifty day simple moving average is $1.26 and its 200-day simple moving average is $1.52. Aptorum Group has a 12 month low of $0.69 and a 12 month high of $4.47.

Wall Street Analysts Forecast Growth

APM has been the topic of several research analyst reports. Wall Street Zen raised Aptorum Group from a “sell” rating to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aptorum Group in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.